8-K: Iris Acquisition Corp. Stockholders Approve Business Combination with Liminatus Pharma

Iris Acquisition Corp. stockholders overwhelmingly approved the business combination with Liminatus Pharma at a special meeting held on March 4, 2025.

Summary

• Iris Acquisition Corp. held a special meeting of stockholders on March 4, 2025, where several proposals were voted on and approved.
• The key proposal was the approval of the business combination agreement with Iris Parent Holding Corp., SPAC Merger Sub, Inc., Liminatus Pharma Merger Sub, Inc., and Liminatus Pharma, LLC.
• Stockholders also approved the issuance of ParentCo common stock, the ParentCo 2025 Omnibus Equity Incentive Plan, and ParentCo's amended and restated certificate of incorporation.
• Advisory proposals related to governance provisions in the ParentCo Certificate of Incorporation were also approved.
• The election of four directors to the board of the post-combination company was approved.
• A proposal to adjourn the meeting was not necessary as sufficient votes were already secured.
• Stockholders holding 59,844 public shares exercised their right to redeem their shares for approximately $11.47 per share, totaling $686,411.
• The company's stock is expected to be delisted from Nasdaq, but this is not expected to have a practical effect as the company's securities have been traded on the OTC Market since September 6, 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the business combination was approved, but tempered by the delisting from Nasdaq. The company anticipates no practical effect from the delisting.

Positives

• The business combination with Liminatus Pharma was approved by stockholders.
• All proposals at the Special Meeting were approved, indicating strong stockholder support.
• The company expects that the final delisting action by Nasdaq will have no practical effect on the trading of its securities on the OTC Market.

Negatives

• The company's common stock is being delisted from Nasdaq.

Risks

• The document contains forward-looking statements that involve risks and uncertainties.
• There is no assurance that the delisting action by Nasdaq will have no practical effect on the trading of the company's securities.

Future Outlook

The company undertakes no obligation to publicly update any forward-looking statements to reflect changes in information, events or circumstances after the date of this report, unless required by law.

Industry Context

This announcement reflects the completion of a key step in the SPAC merger process, which is a common route for private companies to go public. The delisting from Nasdaq and subsequent trading on the OTC market is not uncommon for companies undergoing such transitions.

Comparison to Industry Standards

• SPAC mergers are a common method for companies, particularly in the biotech and pharmaceutical sectors, to access public markets.
• The redemption rate of shares is a key metric in assessing the success of a SPAC merger, with lower redemption rates generally viewed more favorably.
• Comparable companies that have undergone similar SPAC mergers include 23andMe (DNA) and Virgin Galactic (SPCE).

Stakeholder Impact

• Shareholders have approved the business combination, which will result in a new publicly traded entity.
• Employees of both Iris Acquisition Corp. and Liminatus Pharma will be integrated into the new company.
• Customers and partners of Liminatus Pharma can expect continued operations under the new entity.

Next Steps

• Completion of the business combination with Liminatus Pharma.
• Transition of trading to the OTC Market.

Key Dates